Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and …
NF Saba, SJ Hurwitz, K Magliocca, S Kim… - Cancer, 2014 - Wiley Online Library
BACKGROUND Platinum‐based therapy combined with cetuximab is standard first‐line
therapy for recurrent or metastatic squamous cell carcinoma of the head and neck …
therapy for recurrent or metastatic squamous cell carcinoma of the head and neck …
[HTML][HTML] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner, PM Harari, J Giralt, N Azarnia… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a multinational, randomized study to compare radiotherapy
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …
alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal …
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or …
Background Cetuximab based treatment is the recommended chemotherapy for head and
neck squamous cell cancers in the palliative setting. However, due to financial constraints …
neck squamous cell cancers in the palliative setting. However, due to financial constraints …
[HTML][HTML] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A Argiris, AP Kotsakis, T Hoang, FP Worden… - Annals of oncology, 2013 - Elsevier
Background We evaluated combined targeting with cetuximab, an anti-epidermal growth
factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial …
factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial …
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a …
DG Pfister, YB Su, DH Kraus, SL Wolden… - Journal of clinical …, 2006 - ascopubs.org
Purpose Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …
factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both …
[HTML][HTML] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic …
M Tahara, N Kiyota, T Yokota, Y Hasegawa, K Muro… - Annals of …, 2018 - Elsevier
Background The standard of care for first-line treatment of recurrent and/or metastatic
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …
squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with …
The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: evidence …
J Guigay, M Tahara, L Licitra, U Keilholz… - Frontiers in …, 2019 - frontiersin.org
The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-
fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression …
fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression …
Cetuximab and the head and neck squamous cell cancer
R Concu, M Cordeiro - Current topics in medicinal chemistry, 2018 - ingentaconnect.com
The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and
neck cancer (more than 90%), and all over the world more than a half million people have …
neck cancer (more than 90%), and all over the world more than a half million people have …
Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
J Bernier, D Schneider - European Journal of Cancer, 2007 - Elsevier
Radiotherapy remains the foundation of current treatment for patients with locally advanced
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …
squamous cell carcinoma of the head and neck (SCCHN). It has been shown that the …
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally …
Purpose We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal
growth factor receptor (EGFR), into the induction therapy and subsequent …
growth factor receptor (EGFR), into the induction therapy and subsequent …